Terapi Sel Punca Mesenkimal pada Diabetes Melitus Tipe 2: Tinjauan Sistematis terhadap Outcome HbA1c
DOI:
https://doi.org/10.31539/qndx0b97Abstract
This study evaluates the effectiveness of Mesenchymal Stem Cell (MSC) therapy in lowering HbA1c levels among patients with Type 2 Diabetes Mellitus (T2DM). A systematic review was conducted using PubMed, ScienceDirect, and Google Scholar with the keywords “Type 2 Diabetes Mellitus,” “Mesenchymal Stem Cell,” and “HbA1c,” covering studies published between 2022–2025. Four primary studies met the inclusion criteria, involving 438 patients treated with MSCs from various sources. Most studies reported significant HbA1c reduction after MSC infusion, particularly with UC-MSC therapy, which showed a decrease of over 1% within 48 weeks. The effect was more pronounced in patients with a shorter diabetes duration (≤10 years) and lower BMI (<23 kg/m²). The conclusion is that MSC therapy has been proven to improve glycemic control with a favorable safety profile. However, further large-scale and long-term studies are needed to confirm its effectiveness and determine the optimal clinical application.
Keywords: Type 2 Diabetes Mellitus, HbA1c, Mesenchymal Stem Cell
References
Aloke, C., Egwu, C. O., Aja, P. M., Obasi, N. A., Chukwu, J., Akumadu, B. O., Ogbu, P. N., & Achilonu, I. (2022). Current Advances in the Management of Diabetes Mellitus. Biomedicines, 10(10), 2436. https://doi.org/10.3390/biomedicines10102436
Berbudi, A., Khairani, S., & Tjahjadi, A. I. (2025). Interplay between Insulin Resistance and Immune Dysregulation in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions. ImmunoTargets and Therapy, 14(April), 359–382. https://doi.org/10.2147/ITT.S499605
Chai, S., Niu, Y., Liu, F., Wu, S., Yang, Z., & Sun, F. (2024). Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review. Journal of Diabetes Research, 2024, 8145388. https://doi.org/10.1155/2024/8145388
Chen, Y., Wang, G., Hou, Z., Liu, X., Ma, S., & Jiang, M. (2025). Comparative Diabetes Mellitus Burden Trends Across Global, Chinese, US, and Indian Populations Using GBD 2021 Database. Scientific Reports, 15(1), 1–16. https://doi.org/10.1038/s41598-025-96175-4
Chin, S. P., Kee, L. T., Mohd, M. A., & Then, K. Y. (2025). Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Type 2 Diabetes Mellitus Patients: A Retrospective Cytopeutics’ Registry Study. Diabetes, Metabolic Syndrome and Obesity , 18(May), 1643–1659. https://doi.org/10.2147/DMSO.S507801
Gao, S., Zhang, Y., Liang, K., Bi, R., & Du, Y. (2022). Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes. Stem Cells International, 2022, 8637493. https://doi.org/10.1155/2022/8637493
Gieroba, B., Kryska, A., & Sroka-bartnicka, A. (2025). Type 2 Diabetes Mellitus – Conventional Therapies and Future Perspectives in Innovative Treatment. Biochemistry and Biophysics Reports, 42(May), 102037. https://doi.org/10.1016/j.bbrep.2025.102037
Hossain, M. J., Al-Mamun, M., & Islam, M. R. (2024). Diabetes Mellitus, the Fastest Growing Global Public Health Concern: Early Detection Should Be Focused. Health science reports, 7(3), e2004. https://doi.org/10.1002/hsr2.2004
Kashbour, M., Abdelmalik, A., Yassin, M. N. A., Abed, M., Aldieb, E., Abdullah, D. M., Elmozugi, T., Isawi, Y., Hassan, E., & Almuzghi, F. (2025). Mesenchymal Stem Cell-Based Therapy for Type 1 & 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetology and Metabolic Syndrome , 17(1), 189. https://doi.org/10.1186/s13098-025-01619-6
Li, H., Chen, C., Wang, Y., Yi, W., Guo, P., Yao, C., Liu, J., Wei, Y., Hu, K., Shang, X., & Kang, S. (2025). A Meta-Analysis on Application and Prospect of Cell Therapy in the Treatment of Diabetes Mellitus. Stem Cell Research & Therapy, 16(1), 249. https://doi.org/10.1186/s13287-025-04377-4
Lian, X. F., Lu, D. H., Liu, H. L., Liu, Y. J., Han, X. Q., Yang, Y., Lin, Y., Zeng, Q. X., Huang, Z. J., Xie, F., Huang, C. H., Wu, H. M., Long, A. M., Deng, L. P., & Zhang, F. (2022). Effectiveness and Safety of Human Umbilical Cord-Mesenchymal Stem Cells for Treating Type 2 Diabetes Mellitus. World Journal of Diabetes, 13(10), 877–887. https://doi.org/10.4239/wjd.v13.i10.877
Matsuoka, T., Hara, Y., Itohara, T., Ueda, N., Nishimura, K., Ryugo, A., & Kanai, S. (2022). Long-Term E ffi cacy of a Single Intravenous MSC Infusion on HbA1c Reduction in Type 2 Diabetic Mellitus. Biomedical Research, 6(4, 320-327. https://doi.org/10.37871/jbres2087
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025). Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. International Journal of Molecular Sciences, 26(3), 1094. https://doi.org/10.3390/ijms26031094
Perico, N., Remuzzi, G., Griffin, M. D., Cockwell, P., Maxwell, A. P., Casiraghi, F., Rubis, N., Peracchi, T., Villa, A., Todeschini, M., Carrara, F., Magee, B. A., Ruggenenti, P. L., Rota, S., Cappelletti, L., McInerney, V., Griffin, T. P., Islam, M. N., Introna, M., Pedrini, O., & NEPHSTROM Trial Consortium (2023). Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). Journal of the American Society of Nephrology : JASN, 34(10), 1733–1751. https://doi.org/10.1681/ASN.0000000000000189
Shi, Q., Nong, K., Vandvik, P. O., Guyatt, G. H., Schnell, O., Rydén, L., Marx, N., Brosius, F. C., 3rd, Mustafa, R. A., Agarwal, A., Zou, X., Mao, Y., Asadollahifar, A., Chowdhury, S. R., Zhai, C., Gupta, S., Gao, Y., Lima, J. P., Numata, K., Qiao, Z., & Li, S. (2023). Benefits and Harms of Drug Treatment for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. BMJ (Clinical Research ed.), 381, e074068. https://doi.org/10.1136/bmj-2022-074068
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023). Drug Therapies for Diabetes. International Journal of Molecular Sciences, 24(24), 1–20. https://doi.org/10.3390/ijms242417147
Wu, Z., Huang, S., Li, S., Cai, J., Huang, L., Wu, W., Chen, J., & Tan, J. (2024). Bone Marrow Mesenchymal Stem Cell and Mononuclear Cell Combination Therapy In Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study with 8-Year Follow-Up. Stem Cell Research & Therapy, 15(1), 339. https://doi.org/10.1186/s13287-024-03907-w
Yapislar, H., & Gurler, E. B. (2024). Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment. Biomedicines, 12(9), 1–25. https://doi.org/10.3390/biomedicines12091958
Zang, L., Li, Y., Hao, H., Liu, J., Cheng, Y., Li, B., Yin, Y., Zhang, Q., Gao, F., Wang, H., Gu, S., Li, J., Lin, F., Zhu, Y., Tian, G., Chen, Y., Gu, W., Du, J., Chen, K., & Mu, Y. (2022). Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stem Cells in Chinese Adults with Type 2 Diabetes: A Single-Center, Double-Blinded, Randomized, Placebo-Controlled Phase II Trial. Stem Cell Research and Therapy, 13(1), 1–10. https://doi.org/10.1186/s13287-022-02848-6
Zeinhom, A., Fadallah, S. A., & Mahmoud, M. (2024). Human Mesenchymal Stem/Stromal Cell Based-Therapy in Diabetes Mellitus: Experimental and Clinical Perspectives. Stem Cell Research & Therapy, 15(1), 384. https://doi.org/10.1186/s13287-024-03974-z
Downloads
Published
Issue
Section
License
Copyright (c) 2025 M.Nazhim Alhani, Esa Zahirah
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
